Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Mycosis Fungoides 3Multiple Myeloma 3Neoplasms, Plasma Cell 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Burkitt Lymphoma 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Advanced Cancers 1

Interventions

trametinib 2olaparib 1glembatumumab vedotin 1durvalumab 1cediranib 1Vorinostat 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1CR011-vcMMAE 1Biopsy, Fine-Needle 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Uveal Melanoma × Vorinostat × Clear all
NCT03022565 2020-02-06

Vorinostat in Patients With Class 2 High Risk Uveal Melanoma

University of Miami

Phase EARLY_PHASE1 Withdrawn
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡